BNCC has launched HPV E6/E7 RNA standards

Human papillomavirus (HPV) is a familiar term, a major cause of cervical cancer. Globally, over 99% of cervical cancers are related to persistent infection with high-risk HPV types. The E6 and E7 genes of HPV are the core of this carcinogenicity; once activated, they disrupt cellular tumor suppressor mechanisms, leading to abnormal cell proliferation and ultimately cancer. Precise RNA standards are indispensable for HPV testing reagent development, clinical screening quality control, and scientific research.

BNCC HPV E6/E7 RNA standards address the core needs of various testing and research applications. Covering multiple high-risk HPV E6/E7 RNA sequences, they accurately reflect viral load status through absolute determination by digital PCR and relative determination by quantitative real-time PCR. With wide-ranging applications, including HPV-related research experiments, testing reagent validation and evaluation, clinical laboratory quality control, and HPV analysis and identification, they meet diverse needs in research, clinical production, and provide precise quality control, forming a solid first line of defense for HPV testing and research.

BNCC HPV E6/E7 RNA standards support HPV-related research and testing.